A groundbreaking new oral medication for weight management has shown promising results in a recent large-scale clinical trial, offering hope to millions with obesity and related health issues.

Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Analysts expect the pill to be as effective, ...

In addition, the 12 mg and 36 mg doses showed clinically meaningful and statistically significant reductions in body weight vs. placebo. In the study, orforglipron met the primary endpoint of superior ...

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not diabetic, to lose ...

Drugmaker Eli Lilly announced promising Phase 3 study results for its new GLP-1 pill. Orforglipron is a drug similar to Ozempic but without the injection, making it more accessible. The pill, poised ...

(Reuters) -Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results ...

Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Stream Connecticut News for free, 24/7, ...